Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

ASND

Ascendis Pharma A/S ADR

Oct 09 • 10:03AM ET

131.39

Dollar change -0.66
Percentage change -0.50	%

Healthcare • Biotechnology • Denmark • NASD

Peers: ADVM BIIB DNLI EXEL INCY NBIX NKTR REGN SRPT VRTX

| Held by: IBB SPDW MEDI FDG ONEQ HRTS PFUT TMAT FTQI FMED

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-9.34	Insider Own	1.30%	Shs Outstand	56.61M	Perf Week	-10.19%
Market Cap	7.54B	Forward P/E	-	EPS next Y	-3.59	Insider Trans	0.00%	Shs Float	56.61M	Perf Month	14.49%
Income	-529.87M	PEG	-	EPS next Q	-1.70	Inst Own	105.69%	Short Float	5.89%	Perf Quarter	-3.18%
Sales	343.17M	P/S	21.96	EPS this Y	16.73%	Inst Trans	-0.21%	Short Ratio	5.52	Perf Half Y	-13.89%
Book/sh	-6.00	P/B	-	EPS next Y	54.05%	ROA	-61.92%	Short Interest	3.34M	Perf Year	44.34%
Cash/sh	4.83	P/C	27.18	EPS next 5Y	38.95%	ROE	-867.62%	52W Range	85.29 - 161.00	Perf YTD	4.32%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-19.87%	ROI	-	52W High	-18.39%	Beta	0.64
Dividend TTM	-	Quick Ratio	0.44	Sales past 5Y	182.00%	Gross Margin	80.72%	52W Low	54.06%	ATR (14)	5.67
Dividend Ex-Date	-	Current Ratio	0.74	EPS Y/Y TTM	17.33%	Oper. Margin	-111.43%	RSI (14)	41.37	Volatility	3.93% 4.08%
Employees	-	Debt/Eq	-	Sales Y/Y TTM	171.57%	Profit Margin	-154.40%	Recom	1.14	Target Price	194.02
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	12.65%	Payout	-	Rel Volume	0.30	Prev Close	132.05
Sales Surprise	-56.76%	EPS Surprise	-30.53%	Sales Q/Q	-24.87%	Earnings	Sep 03 AMC	Avg Volume	604.69K	Price	131.39
SMA20	-7.17%	SMA50	-2.94%	SMA200	-4.55%	Trades		Volume	23,652	Change	-0.50%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-05-24	Upgrade	Oppenheimer	Perform → Outperform	$180
Jun-25-24	Upgrade	TD Cowen	Hold → Buy	$156 → $175
May-31-24	Initiated	Stifel	Buy	$200
Dec-20-23	Initiated	Jefferies	Buy	$150
Jun-14-23	Resumed	Credit Suisse	Neutral	$89
Apr-05-23	Downgrade	Oppenheimer	Outperform → Perform
Apr-04-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$151 → $108
Apr-03-23	Downgrade	Credit Suisse	Outperform → Neutral
Oct-20-22	Initiated	Goldman	Buy	$174
Aug-30-22	Resumed	Berenberg	Buy	$166
Mar-28-22	Resumed	Wedbush	Outperform	$163
Mar-15-22	Upgrade	BofA Securities	Neutral → Buy	$148 → $161
Mar-01-22	Initiated	Citigroup	Buy	$187
Feb-14-22	Upgrade	Oppenheimer	Perform → Outperform	$170
Jan-06-22	Initiated	Cowen	Market Perform	$136
Dec-08-21	Initiated	Wells Fargo	Overweight	$176
Oct-20-21	Downgrade	BofA Securities	Buy → Neutral	$164 → $169
Mar-30-21	Downgrade	Oppenheimer	Outperform → Perform
Mar-11-21	Resumed	Stifel	Buy	$190
Dec-17-20	Initiated	Berenberg	Buy	$216

Show Previous Ratings

Oct-01-24 10:13AM	Ascendis Pharma submits sBLA for growth hormone deficiency therapy (Pharmaceutical Technology)
Sep-30-24 08:30AM	New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon PTH (Palopegteriparatide) Presented at ASBMR 2024 (GlobeNewswire)
08:30AM	Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon hGH for the Treatment of Adults with Growth Hormone Deficiency (GlobeNewswire)
Sep-25-24 03:50PM	BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish (Benzinga)
Sep-19-24 08:16PM	Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs (GlobeNewswire)
04:04PM	Loading…
Sep-18-24 04:04PM	Ascendis Pharma A/S Announces Proposed Public Offering of ADSs (GlobeNewswire)
Sep-17-24 09:02AM	Ascendis Pharma (ASND) Moves 17.1% Higher: Will This Strength Last? (Zacks) +5.03%
01:30AM	RA Capital Management's Strategic Acquisition of Fulcrum Therapeutics Shares (GuruFocus.com)
Sep-16-24 04:01PM	Ascendis Rockets And Hammers BioMarin On New Results For Growth Drug (Investor's Business Daily) +17.07%
03:12PM	Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term (Benzinga)
07:00AM	Pivotal ApproaCH Trial of TransCon CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo (GlobeNewswire)
Sep-14-24 07:54PM	Ascendis Pharma A/S (ASND): Among Hedge Funds Top Biotech Stock Picks (Insider Monkey)
Sep-13-24 08:30AM	Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024 (GlobeNewswire)
Sep-11-24 05:37PM	Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH (Palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults (GlobeNewswire)
Sep-04-24 05:02PM	Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In (Benzinga) -11.27%
04:48PM	Loading…
04:48PM	Why Ascendis Pharma Stock Tumbled by 11% Today (Motley Fool)
04:02PM	Ascendis Pharma Undercuts 50-Day Line After Pricing Fiasco Prompts Guidance Cut (Investor's Business Daily)
09:14AM	Ascendis Pharma Slashes Its Outlook Amid Pricing Fiasco, Sacrifices A Breakout (Investor's Business Daily)
Sep-03-24 05:14PM	Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement (GlobeNewswire)
05:06PM	Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement (GlobeNewswire)
05:04PM	Ascendis Pharma Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Sep-02-24 09:01AM	Ascendis Pharma A/S (ASND) Q2 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Aug-28-24 08:30AM	Ascendis Pharma to Report Second Quarter 2024 Financial Results and Provide Business Update on September 3, 2024 (GlobeNewswire)
Aug-14-24 12:31PM	Ascendis (ASND) Up on FDA Nod for Hormone Therapy Yorvipath (Zacks)
08:59AM	Ascendis Pharma (ASND) Surges 8.7%: Is This an Indication of Further Gains? (Zacks)
Aug-13-24 04:32AM	FDA approves Ascendis Pharmas YORVIPATH for hypoparathyroidism (Pharmaceutical Technology) +8.70%
Aug-12-24 04:55PM	Ascendis Pharma Zips Higher After FDA Approves Embattled Drug (Investor's Business Daily)
07:30AM	FDA approves Ascendis drug for rare endocrine condition (BioPharma Dive)
07:00AM	FDA Approves YORVIPATH (Palopegteriparatide) as the First and Only Treatment for Hypoparathyroidism in Adults (GlobeNewswire)
Jul-07-24 09:01AM	2 Biotech Stocks With Big FDA Decisions Approaching Heres What Analysts Expect (TipRanks)
06:33AM	Loading…
Jul-05-24 06:33AM	Pendopharm and Ascendis to distribute hypoparathyroidism treatment (Pharmaceutical Technology)
Jul-04-24 12:48PM	Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransCon PTH in Canada (PR Newswire)
Jun-24-24 04:45PM	Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024 (GlobeNewswire)
Jun-21-24 01:02AM	Ascendis Pharma A/S (ASND) Stock Soared on Unexpected Demand (Insider Monkey) +5.12%
Jun-04-24 04:01PM	Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
Jun-03-24 04:01PM	Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024 (GlobeNewswire)
May-30-24 08:30AM	Ascendis to Spotlight Latest Updates for TransCon Rare Endocrinology Disease Portfolio at ENDO 2024 (GlobeNewswire)
May-15-24 01:57PM	FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months (Benzinga)
10:44AM	FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing (Zacks)
May-14-24 04:07PM	US Equity Markets Close Higher Tuesday as Producer Prices Rise (MT Newswires) -5.45%
03:20PM	Ascendis Pharma Says US FDA Extends Review Period on Hypoparathyroidism Treatment; Shares Drop (MT Newswires)
02:47PM	UPDATE 2-US FDA extends review of Ascendis Pharma's hormone disorder therapy (Reuters)
02:38PM	FDA extends review of Ascendis Pharma's hormone disorder therapy (Reuters)
02:31PM	Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon PTH for Adults with Hypoparathyroidism (GlobeNewswire)
May-13-24 09:29AM	Ascendis Says Late-Stage Trial Shows 'Significant' Improvements in Kidney Function for Adults Treated With TransCon PTH (MT Newswires)
08:30AM	Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial (GlobeNewswire)
May-09-24 08:30AM	Latest Clinical and Quality-of-Life Data for TransCon PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024 (GlobeNewswire)
May-06-24 09:59AM	Ascendis Pharma A/S (NASDAQ:ASND) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-03-24 03:49AM	Ascendis Pharma Q1 Net Loss Widens, Revenue Rises (MT Newswires)
May-02-24 09:57PM	ASND Stock Earnings: Ascendis Pharma Reported Results for Q1 2024 (InvestorPlace)
04:01PM	Ascendis Pharma Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-25-24 04:46PM	Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024 (GlobeNewswire)
Apr-24-24 11:33AM	Ascendis Pharma Gets UK Regulator's Approval for Yorvipath to Treat Hypoparathyroidism (MT Newswires)
08:34AM	Why Earnings Season Could Be Great for Ascendis Pharma (ASND) (Zacks)
08:30AM	United Kingdom's MHRA Approves YORVIPATH (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism (GlobeNewswire)
Apr-02-24 06:13AM	Biotech With 520% Sales Growth Nears Next Buy Point (Investor's Business Daily)
Mar-22-24 12:09PM	Two Health Care Stocks Outperform S&P 500, Offer Entries (Investor's Business Daily)
05:27AM	Ascendis Pharma A/S (ASND) Rose on Positive Trial Results (Insider Monkey)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-07-24 08:14AM	Ascendis Pharma A/S (ASND) Faced R&D Setbacks in Q4 (Insider Monkey)
Mar-04-24 08:30AM	Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024 (GlobeNewswire)
Feb-15-24 12:00PM	Ascendis Pharma A/S (ASND) is a Great Momentum Stock: Should You Buy? (Zacks)
09:40AM	Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year? (Zacks)
Feb-08-24 10:07AM	Ascendis Pharma A/S (NASDAQ:ASND) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-07-24 04:01PM	Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results (GlobeNewswire)
08:30AM	Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Feb-06-24 08:46AM	Why Earnings Season Could Be Great for Ascendis Pharma (ASND) (Zacks)
Jan-31-24 04:15PM	Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024 (GlobeNewswire) +9.00%
04:01PM	Ascendis Pharma Launches 2nd TransCon Product: YORVIPATH Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism (GlobeNewswire)
Jan-29-24 08:30AM	New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors (GlobeNewswire)
Jan-08-24 06:01PM	Er-Kim Announces Exclusive Distribution Agreement with Ascendis Pharma A/S to Commercialize 3 Endocrinology Disease Treatments Across Central & Eastern Europe and Turkey (GlobeNewswire) +6.57%
08:20AM	Vector Pharma FZCO Announce Exclusive Distribution Agreement with Ascendis Pharma A/S for Skytrofa (lonapegsomatropin) and Yorvipath (palopegteriparatide) in Gulf Cooperation Council Countries (GlobeNewswire)
Jan-07-24 05:45PM	Ascendis Pharma Introduces Vision 2030 (GlobeNewswire)
02:00PM	Specialised Therapeutics signs exclusive agreement with Ascendis Pharma A/S for distribution and commercialisation of three endocrinology therapies in Australia and select South-East Asia countries (PR Newswire)
Dec-28-23 04:15PM	Ascendis Pharma to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-20-23 08:30AM	Significant Health and Quality of Life Improvements Achieved in Children with Achondroplasia Treated for One Year with TransCon CNP (Navepegritide) at 100 g/kg/week (GlobeNewswire)
Dec-19-23 08:30AM	TransCon hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency (GlobeNewswire)
Dec-11-23 08:30AM	FDA Accepts for Review Resubmitted NDA for TransCon PTH (Palopegteriparatide) in Adult Patients with Hypoparathyroidism (GlobeNewswire)
Nov-29-23 04:30AM	Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan (GlobeNewswire) +7.12%
Nov-20-23 08:00AM	Ascendis Pharma Announces European Commission Approval of YORVIPATH (palopegteriparatide) for the Treatment of Adults with Chronic Hypoparathyroidism (GlobeNewswire)
Nov-15-23 08:00AM	Ascendis Pharma Resubmits NDA for TransCon PTH to the U.S. FDA (GlobeNewswire)
Nov-08-23 02:07PM	Ascendis Pharma A/S (NASDAQ:ASND) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 04:01PM	Ascendis Pharma Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-01-23 09:55AM	Does Ascendis Pharma A/S (ASND) Have the Potential to Rally 51.72% as Wall Street Analysts Expect? (Zacks)
Oct-31-23 08:30AM	Ascendis Pharma Announces Timing of Third Quarter 2023 Financial Results and TransCon PTH NDA Resubmission (GlobeNewswire)
Oct-26-23 09:35AM	Ascendis Pharma A/S (ASND) Loses -8.26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
08:30AM	Ascendis Presents Updated and New TransCon IL-2 Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types at ESMO 2023 (GlobeNewswire)
Oct-16-23 04:01PM	Ascendis Pharma Presents TransCon PTH (palopegteriparatide) Phase 3 52-Week Skeletal Dynamics Data at ASBMR 2023 (GlobeNewswire)
Oct-02-23 08:00AM	Ascendis Presents TransCon PTH Data at the American Thyroid Association Annual Meeting (GlobeNewswire)
Sep-23-23 07:00AM	Ascendis Pharma Presents Results from Long-Term enliGHten Trial of TransCon hGH in Pediatric Growth Hormone Deficiency (GlobeNewswire)
Sep-22-23 09:24AM	Heres What Caused the Volatility in Ascendis Pharma A/S (ASND) (Insider Monkey)
Sep-15-23 08:00AM	Ascendis Pharma Launches SKYTROFA® (lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency (GlobeNewswire)
07:27AM	Ascendis Pharma A/S (ASND) Soars 3.2%: Is Further Upside Left in the Stock? (Zacks)
Sep-14-23 12:22PM	Ascendis Pharma Receives Positive CHMP Opinion for TransCon PTH (palopegteriparatide) for Adults with Chronic Hypoparathyroidism (GlobeNewswire)
Sep-06-23 12:11PM	Ascendis Pharma A/S (ASND): A Deep Dive into Its Performance Potential (GuruFocus.com)
11:41AM	Is Ascendis Pharma A/S (ASND) Too Good to Be True? A Comprehensive Analysis of a Potential ... (GuruFocus.com)
08:21AM	Ascendis Pharma A/S (NASDAQ:ASND) Q2 2023 Earnings Call Transcript (Insider Monkey)
Sep-05-23 04:15PM	Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement (GlobeNewswire)
04:03PM	Ascendis Pharma Reports Second Quarter 2023 Financial Results (GlobeNewswire)
04:01PM	New Post Hoc Analysis Showed Substantial Improvement in Observed Estimated Glomerular Filtration Rate (eGFR), in TransCon PTH-Treated Adults with Hypoparathyroidism (GlobeNewswire)

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ASND

Ascendis Pharma A/S ADR

Upgrade your FINVIZ experience